aluates Reports

$ 0.0

Automative

Psychedelic Drugs - Global Market Insights and Sales Trends 2024

Published Date: 2023-12-27

Report Code: QYRE-Auto-38Y9909

Global Psychedelic Drugs Market Insights Forecast to 2028

BUY CHAPTERS

Psychedelic Drugs - Global Market Insights and Sales Trends 2024

Code: QYRE-Auto-38Y9909

Report

2023-12-27

Pages:122

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Psychedelic Drugs - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Psychedelic Drugs - Market

The global Psychedelic Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Psychedelic Drugs in various end use industries. The expanding demands from the Depressive Disorders, Post-Traumatic Stress Disorders, Substance Abuse Disorders and Obsessive Compulsive Disorders, are propelling Psychedelic Drugs market. Psilocybin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the LSD segment is estimated at % CAGR for the next seven-year period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Psychedelic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Psychedelic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Psychedelic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Psychedelic Drugs sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Psychedelic Drugs covered in this report include COMPASS Pathways PLC, Pfizer, Eli Lilly, GlaxoSmithKline, Cybin Inc, Field Trip Health, ATAI Life Sciences, NUMINUS WELLNESS and MindMed, etc.

The global Psychedelic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

COMPASS Pathways PLC

Pfizer

Eli Lilly

GlaxoSmithKline

Cybin Inc

Field Trip Health

ATAI Life Sciences

NUMINUS WELLNESS

MindMed

HAVN Life Sciences

Seelos Therapeutics

Jannsen

Acadia Pharmaceuticals

Intellipharmaceutics

Revive Therapeutics

Mydecine Innovations Group

Red Light Holland

Braxia Scientific

Mind Cure Health

Entheon Biomedical

Scope of Psychedelic Drugs - Market Report

Report Metric	Details
Report Name	Psychedelic Drugs - Market
CAGR	5%
Global Psychedelic Drugs market, by region:	North America (U.S., Canada, Mexico) Europe (Germany, France, UK, Italy, etc.) Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.) South America (Brazil, etc.) Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Psychedelic Drugs market, Segment by Type:	Psilocybin LSD MDMA DMT Ketamine Others
Global Psychedelic Drugs market, by Application	Depressive Disorders Post-Traumatic Stress Disorders Substance Abuse Disorders Obsessive Compulsive Disorders Others
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Psychedelic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

FAQ for this report

What are the Application segmentation covered in the Psychedelic Drugs - Market report?

Ans: The Applications covered in the Psychedelic Drugs - Market report are Depressive Disorders, Post-Traumatic Stress Disorders, Substance Abuse Disorders, Obsessive Compulsive Disorders, Others

What are the Type segmentation covered in the Psychedelic Drugs - Market report?

Ans: The Types covered in the Psychedelic Drugs - Market report are Psilocybin, LSD, MDMA, DMT, Ketamine, Others

1 Market Overview of Psychedelic Drugs

1.1 Psychedelic Drugs Market Overview

1.1.1 Psychedelic Drugs Product Scope

1.1.2 Psychedelic Drugs Market Status and Outlook

1.2 Global Psychedelic Drugs Market Size Overview by Region 2018 VS 2022 VS 2029

1.3 Global Psychedelic Drugs Market Size by Region (2018-2029)

1.4 Global Psychedelic Drugs Historic Market Size by Region (2018-2023)

1.5 Global Psychedelic Drugs Market Size Forecast by Region (2024-2029)

1.6 Key Regions, Psychedelic Drugs Market Size (2018-2029)

1.6.1 North America Psychedelic Drugs Market Size (2018-2029)

1.6.2 Europe Psychedelic Drugs Market Size (2018-2029)

1.6.3 Asia-Pacific Psychedelic Drugs Market Size (2018-2029)

1.6.4 Latin America Psychedelic Drugs Market Size (2018-2029)

1.6.5 Middle East & Africa Psychedelic Drugs Market Size (2018-2029)

2 Psychedelic Drugs Market by Type

2.1 Introduction

2.1.1 Psilocybin

2.1.2 LSD

2.1.3 MDMA

2.1.4 DMT

2.1.5 Ketamine

2.1.6 Others

2.2 Global Psychedelic Drugs Market Size by Type: 2018 VS 2022 VS 2029

2.2.1 Global Psychedelic Drugs Historic Market Size by Type (2018-2023)

2.2.2 Global Psychedelic Drugs Forecasted Market Size by Type (2024-2029)

2.3 Key Regions Market Size by Type

2.3.1 North America Psychedelic Drugs Revenue Breakdown by Type (2018-2029)

2.3.2 Europe Psychedelic Drugs Revenue Breakdown by Type (2018-2029)

2.3.3 Asia-Pacific Psychedelic Drugs Revenue Breakdown by Type (2018-2029)

2.3.4 Latin America Psychedelic Drugs Revenue Breakdown by Type (2018-2029)

2.3.5 Middle East and Africa Psychedelic Drugs Revenue Breakdown by Type (2018-2029)

3 Psychedelic Drugs Market Overview by Application

3.1 Introduction

3.1.1 Depressive Disorders

3.1.2 Post-Traumatic Stress Disorders

3.1.3 Substance Abuse Disorders

3.1.4 Obsessive Compulsive Disorders

3.1.5 Others

3.2 Global Psychedelic Drugs Market Size by Application: 2018 VS 2022 VS 2029

3.2.1 Global Psychedelic Drugs Historic Market Size by Application (2018-2023)

3.2.2 Global Psychedelic Drugs Forecasted Market Size by Application (2024-2029)

3.3 Key Regions Market Size by Application

3.3.1 North America Psychedelic Drugs Revenue Breakdown by Application (2018-2029)

3.3.2 Europe Psychedelic Drugs Revenue Breakdown by Application (2018-2029)

3.3.3 Asia-Pacific Psychedelic Drugs Revenue Breakdown by Application (2018-2029)

3.3.4 Latin America Psychedelic Drugs Revenue Breakdown by Application (2018-2029)

3.3.5 Middle East and Africa Psychedelic Drugs Revenue Breakdown by Application (2018-2029)

4 Psychedelic Drugs Competition Analysis by Players

4.1 Global Psychedelic Drugs Market Size by Players (2018-2023)

4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2022)

4.3 Date of Key Players Enter into Psychedelic Drugs Market

4.4 Global Top Players Psychedelic Drugs Headquarters and Area Served

4.5 Key Players Psychedelic Drugs Product Solution and Service

4.6 Competitive Status

4.6.1 Psychedelic Drugs Market Concentration Rate

4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles

5.1 COMPASS Pathways PLC

5.1.1 COMPASS Pathways PLC Profile

5.1.2 COMPASS Pathways PLC Main Business

5.1.3 COMPASS Pathways PLC Psychedelic Drugs Products, Services and Solutions

5.1.4 COMPASS Pathways PLC Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.1.5 COMPASS Pathways PLC Recent Developments

5.2 Pfizer

5.2.1 Pfizer Profile

5.2.2 Pfizer Main Business

5.2.3 Pfizer Psychedelic Drugs Products, Services and Solutions

5.2.4 Pfizer Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.2.5 Pfizer Recent Developments

5.3 Eli Lilly

5.3.1 Eli Lilly Profile

5.3.2 Eli Lilly Main Business

5.3.3 Eli Lilly Psychedelic Drugs Products, Services and Solutions

5.3.4 Eli Lilly Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.3.5 GlaxoSmithKline Recent Developments

5.4 GlaxoSmithKline

5.4.1 GlaxoSmithKline Profile

5.4.2 GlaxoSmithKline Main Business

5.4.3 GlaxoSmithKline Psychedelic Drugs Products, Services and Solutions

5.4.4 GlaxoSmithKline Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.4.5 GlaxoSmithKline Recent Developments

5.5 Cybin Inc

5.5.1 Cybin Inc Profile

5.5.2 Cybin Inc Main Business

5.5.3 Cybin Inc Psychedelic Drugs Products, Services and Solutions

5.5.4 Cybin Inc Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.5.5 Cybin Inc Recent Developments

5.6 Field Trip Health

5.6.1 Field Trip Health Profile

5.6.2 Field Trip Health Main Business

5.6.3 Field Trip Health Psychedelic Drugs Products, Services and Solutions

5.6.4 Field Trip Health Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.6.5 Field Trip Health Recent Developments

5.7 ATAI Life Sciences

5.7.1 ATAI Life Sciences Profile

5.7.2 ATAI Life Sciences Main Business

5.7.3 ATAI Life Sciences Psychedelic Drugs Products, Services and Solutions

5.7.4 ATAI Life Sciences Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.7.5 ATAI Life Sciences Recent Developments

5.8 NUMINUS WELLNESS

5.8.1 NUMINUS WELLNESS Profile

5.8.2 NUMINUS WELLNESS Main Business

5.8.3 NUMINUS WELLNESS Psychedelic Drugs Products, Services and Solutions

5.8.4 NUMINUS WELLNESS Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.8.5 NUMINUS WELLNESS Recent Developments

5.9 MindMed

5.9.1 MindMed Profile

5.9.2 MindMed Main Business

5.9.3 MindMed Psychedelic Drugs Products, Services and Solutions

5.9.4 MindMed Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.9.5 MindMed Recent Developments

5.10 HAVN Life Sciences

5.10.1 HAVN Life Sciences Profile

5.10.2 HAVN Life Sciences Main Business

5.10.3 HAVN Life Sciences Psychedelic Drugs Products, Services and Solutions

5.10.4 HAVN Life Sciences Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.10.5 HAVN Life Sciences Recent Developments

5.11 Seelos Therapeutics

5.11.1 Seelos Therapeutics Profile

5.11.2 Seelos Therapeutics Main Business

5.11.3 Seelos Therapeutics Psychedelic Drugs Products, Services and Solutions

5.11.4 Seelos Therapeutics Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.11.5 Seelos Therapeutics Recent Developments

5.12 Jannsen

5.12.1 Jannsen Profile

5.12.2 Jannsen Main Business

5.12.3 Jannsen Psychedelic Drugs Products, Services and Solutions

5.12.4 Jannsen Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.12.5 Jannsen Recent Developments

5.13 Acadia Pharmaceuticals

5.13.1 Acadia Pharmaceuticals Profile

5.13.2 Acadia Pharmaceuticals Main Business

5.13.3 Acadia Pharmaceuticals Psychedelic Drugs Products, Services and Solutions

5.13.4 Acadia Pharmaceuticals Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.13.5 Acadia Pharmaceuticals Recent Developments

5.14 Intellipharmaceutics

5.14.1 Intellipharmaceutics Profile

5.14.2 Intellipharmaceutics Main Business

5.14.3 Intellipharmaceutics Psychedelic Drugs Products, Services and Solutions

5.14.4 Intellipharmaceutics Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.14.5 Intellipharmaceutics Recent Developments

5.15 Revive Therapeutics

5.15.1 Revive Therapeutics Profile

5.15.2 Revive Therapeutics Main Business

5.15.3 Revive Therapeutics Psychedelic Drugs Products, Services and Solutions

5.15.4 Revive Therapeutics Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.15.5 Revive Therapeutics Recent Developments

5.16 Mydecine Innovations Group

5.16.1 Mydecine Innovations Group Profile

5.16.2 Mydecine Innovations Group Main Business

5.16.3 Mydecine Innovations Group Psychedelic Drugs Products, Services and Solutions

5.16.4 Mydecine Innovations Group Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.16.5 Mydecine Innovations Group Recent Developments

5.17 Red Light Holland

5.17.1 Red Light Holland Profile

5.17.2 Red Light Holland Main Business

5.17.3 Red Light Holland Psychedelic Drugs Products, Services and Solutions

5.17.4 Red Light Holland Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.17.5 Red Light Holland Recent Developments

5.18 Braxia Scientific

5.18.1 Braxia Scientific Profile

5.18.2 Braxia Scientific Main Business

5.18.3 Braxia Scientific Psychedelic Drugs Products, Services and Solutions

5.18.4 Braxia Scientific Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.18.5 Braxia Scientific Recent Developments

5.19 Mind Cure Health

5.19.1 Mind Cure Health Profile

5.19.2 Mind Cure Health Main Business

5.19.3 Mind Cure Health Psychedelic Drugs Products, Services and Solutions

5.19.4 Mind Cure Health Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.19.5 Mind Cure Health Recent Developments

5.20 Entheon Biomedical

5.20.1 Entheon Biomedical Profile

5.20.2 Entheon Biomedical Main Business

5.20.3 Entheon Biomedical Psychedelic Drugs Products, Services and Solutions

5.20.4 Entheon Biomedical Psychedelic Drugs Revenue (US$ Million) & (2018-2023)

5.20.5 Entheon Biomedical Recent Developments

6 North America

6.1 North America Psychedelic Drugs Market Size by Country (2018-2029)

6.2 United States

6.3 Canada

7 Europe

7.1 Europe Psychedelic Drugs Market Size by Country (2018-2029)

7.2 Germany

7.3 France

7.4 U.K.

7.5 Italy

7.6 Russia

7.7 Nordic Countries

7.8 Rest of Europe

8 Asia-Pacific

8.1 Asia-Pacific Psychedelic Drugs Market Size by Region (2018-2029)

8.2 China

8.3 Japan

8.4 South Korea

8.5 Southeast Asia

8.6 India

8.7 Australia

8.8 Rest of Asia-Pacific

9 Latin America

9.1 Latin America Psychedelic Drugs Market Size by Country (2018-2029)

9.2 Mexico

9.3 Brazil

9.4 Rest of Latin America

10 Middle East & Africa

10.1 Middle East & Africa Psychedelic Drugs Market Size by Country (2018-2029)

10.2 Turkey

10.3 Saudi Arabia

10.4 UAE

10.5 Rest of Middle East & Africa

11 Psychedelic Drugs Market Dynamics

11.1 Psychedelic Drugs Industry Trends

11.2 Psychedelic Drugs Market Drivers

11.3 Psychedelic Drugs Market Challenges

11.4 Psychedelic Drugs Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

13.4 Author List

List of Tables

Table 1. Global Market Psychedelic Drugs Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029

Table 2. Global Psychedelic Drugs Market Size by Region (2018-2023) & (US$ Million)

Table 3. Global Psychedelic Drugs Market Size Share by Region (2018-2023)

Table 4. Global Psychedelic Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)

Table 5. Global Psychedelic Drugs Forecasted Market Size Share by Region (2024-2029)

Table 6. Global Psychedelic Drugs Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029

Table 7. Global Psychedelic Drugs Market Size by Type (2018-2023) & (US$ Million)

Table 8. Global Psychedelic Drugs Revenue Market Share by Type (2018-2023)

Table 9. Global Psychedelic Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)

Table 10. Global Psychedelic Drugs Revenue Market Share by Type (2024-2029)

Table 11. North America Psychedelic Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 12. North America Psychedelic Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 13. Europe Psychedelic Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 14. Europe Psychedelic Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 15. Asia-Pacific Psychedelic Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 16. Asia-Pacific Psychedelic Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 17. Latin America Psychedelic Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 18. Latin America Psychedelic Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 19. Middle East and Africa Psychedelic Drugs Revenue by Type (2018-2023) & (US$ Million)

Table 20. Middle East and Africa Psychedelic Drugs Revenue by Type (2024-2029) & (US$ Million)

Table 21. Global Psychedelic Drugs Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029

Table 22. Global Psychedelic Drugs Market Size by Application (2018-2023) & (US$ Million)

Table 23. Global Psychedelic Drugs Revenue Market Share by Application (2018-2023)

Table 24. Global Psychedelic Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)

Table 25. Global Psychedelic Drugs Revenue Market Share by Application (2024-2029)

Table 26. North America Psychedelic Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 27. North America Psychedelic Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 28. Europe Psychedelic Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 29. Europe Psychedelic Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 30. Asia-Pacific Psychedelic Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 31. Asia-Pacific Psychedelic Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 32. Latin America Psychedelic Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 33. Latin America Psychedelic Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 34. Middle East and Africa Psychedelic Drugs Revenue by Application (2018-2023) & (US$ Million)

Table 35. Middle East and Africa Psychedelic Drugs Revenue by Application (2024-2029) & (US$ Million)

Table 36. Global Psychedelic Drugs Revenue (US$ Million) by Players (2018-2023)

Table 37. Global Psychedelic Drugs Revenue Market Share by Players (2018-2023)

Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2022)

Table 39. Date of Key Players Enter into Psychedelic Drugs Market

Table 40. Global Psychedelic Drugs Key Players Headquarters and Area Served

Table 41. Psychedelic Drugs Product Solution and Service

Table 42. Global Psychedelic Drugs Players Market Concentration Ratio (CR5 and HHI)

Table 43. Mergers & Acquisitions, Expansion Plans

Table 44. COMPASS Pathways PLC Basic Information List

Table 45. COMPASS Pathways PLC Description and Business Overview

Table 46. COMPASS Pathways PLC Psychedelic Drugs Products, Services and Solutions

Table 47. Revenue (US$ Million) in Psychedelic Drugs Business of COMPASS Pathways PLC (2018-2023)

Table 48. COMPASS Pathways PLC Recent Developments

Table 49. Pfizer Basic Information List

Table 50. Pfizer Description and Business Overview

Table 51. Pfizer Psychedelic Drugs Products, Services and Solutions

Table 52. Revenue (US$ Million) in Psychedelic Drugs Business of Pfizer (2018-2023)

Table 53. Pfizer Recent Developments

Table 54. Eli Lilly Basic Information List

Table 55. Eli Lilly Description and Business Overview

Table 56. Eli Lilly Psychedelic Drugs Products, Services and Solutions

Table 57. Revenue (US$ Million) in Psychedelic Drugs Business of Eli Lilly (2018-2023)

Table 58. Eli Lilly Recent Developments

Table 59. GlaxoSmithKline Basic Information List

Table 60. GlaxoSmithKline Description and Business Overview

Table 61. GlaxoSmithKline Psychedelic Drugs Products, Services and Solutions

Table 62. Revenue (US$ Million) in Psychedelic Drugs Business of GlaxoSmithKline (2018-2023)

Table 63. GlaxoSmithKline Recent Developments

Table 64. Cybin Inc Basic Information List

Table 65. Cybin Inc Description and Business Overview

Table 66. Cybin Inc Psychedelic Drugs Products, Services and Solutions

Table 67. Revenue (US$ Million) in Psychedelic Drugs Business of Cybin Inc (2018-2023)

Table 68. Cybin Inc Recent Developments

Table 69. Field Trip Health Basic Information List

Table 70. Field Trip Health Description and Business Overview

Table 71. Field Trip Health Psychedelic Drugs Products, Services and Solutions

Table 72. Revenue (US$ Million) in Psychedelic Drugs Business of Field Trip Health (2018-2023)

Table 73. Field Trip Health Recent Developments

Table 74. ATAI Life Sciences Basic Information List

Table 75. ATAI Life Sciences Description and Business Overview

Table 76. ATAI Life Sciences Psychedelic Drugs Products, Services and Solutions

Table 77. Revenue (US$ Million) in Psychedelic Drugs Business of ATAI Life Sciences (2018-2023)

Table 78. ATAI Life Sciences Recent Developments

Table 79. NUMINUS WELLNESS Basic Information List

Table 80. NUMINUS WELLNESS Description and Business Overview

Table 81. NUMINUS WELLNESS Psychedelic Drugs Products, Services and Solutions

Table 82. Revenue (US$ Million) in Psychedelic Drugs Business of NUMINUS WELLNESS (2018-2023)

Table 83. NUMINUS WELLNESS Recent Developments

Table 84. MindMed Basic Information List

Table 85. MindMed Description and Business Overview

Table 86. MindMed Psychedelic Drugs Products, Services and Solutions

Table 87. Revenue (US$ Million) in Psychedelic Drugs Business of MindMed (2018-2023)

Table 88. MindMed Recent Developments

Table 89. HAVN Life Sciences Basic Information List

Table 90. HAVN Life Sciences Description and Business Overview

Table 91. HAVN Life Sciences Psychedelic Drugs Products, Services and Solutions

Table 92. Revenue (US$ Million) in Psychedelic Drugs Business of HAVN Life Sciences (2018-2023)

Table 93. HAVN Life Sciences Recent Developments

Table 94. Seelos Therapeutics Basic Information List

Table 95. Seelos Therapeutics Description and Business Overview

Table 96. Seelos Therapeutics Psychedelic Drugs Products, Services and Solutions

Table 97. Revenue (US$ Million) in Psychedelic Drugs Business of Seelos Therapeutics (2018-2023)

Table 98. Seelos Therapeutics Recent Developments

Table 99. Jannsen Basic Information List

Table 100. Jannsen Description and Business Overview

Table 101. Jannsen Psychedelic Drugs Products, Services and Solutions

Table 102. Revenue (US$ Million) in Psychedelic Drugs Business of Jannsen (2018-2023)

Table 103. Jannsen Recent Developments

Table 104. Acadia Pharmaceuticals Basic Information List

Table 105. Acadia Pharmaceuticals Description and Business Overview

Table 106. Acadia Pharmaceuticals Psychedelic Drugs Products, Services and Solutions

Table 107. Revenue (US$ Million) in Psychedelic Drugs Business of Acadia Pharmaceuticals (2018-2023)

Table 108. Acadia Pharmaceuticals Recent Developments

Table 109. Intellipharmaceutics Basic Information List

Table 110. Intellipharmaceutics Description and Business Overview

Table 111. Intellipharmaceutics Psychedelic Drugs Products, Services and Solutions

Table 112. Revenue (US$ Million) in Psychedelic Drugs Business of Intellipharmaceutics (2018-2023)

Table 113. Intellipharmaceutics Recent Developments

Table 114. Revive Therapeutics Basic Information List

Table 115. Revive Therapeutics Description and Business Overview

Table 116. Revive Therapeutics Psychedelic Drugs Products, Services and Solutions

Table 117. Revenue (US$ Million) in Psychedelic Drugs Business of Revive Therapeutics (2018-2023)

Table 118. Revive Therapeutics Recent Developments

Table 119. Mydecine Innovations Group Basic Information List

Table 120. Mydecine Innovations Group Description and Business Overview

Table 121. Mydecine Innovations Group Psychedelic Drugs Products, Services and Solutions

Table 122. Revenue (US$ Million) in Psychedelic Drugs Business of Mydecine Innovations Group (2018-2023)

Table 123. Mydecine Innovations Group Recent Developments

Table 124. Red Light Holland Basic Information List

Table 125. Red Light Holland Description and Business Overview

Table 126. Red Light Holland Psychedelic Drugs Products, Services and Solutions

Table 127. Revenue (US$ Million) in Psychedelic Drugs Business of Red Light Holland (2018-2023)

Table 128. Red Light Holland Recent Developments

Table 129. Braxia Scientific Basic Information List

Table 130. Braxia Scientific Description and Business Overview

Table 131. Braxia Scientific Psychedelic Drugs Products, Services and Solutions

Table 132. Revenue (US$ Million) in Psychedelic Drugs Business of Braxia Scientific (2018-2023)

Table 133. Braxia Scientific Recent Developments

Table 134. Mind Cure Health Basic Information List

Table 135. Mind Cure Health Description and Business Overview

Table 136. Mind Cure Health Psychedelic Drugs Products, Services and Solutions

Table 137. Revenue (US$ Million) in Psychedelic Drugs Business of Mind Cure Health (2018-2023)

Table 138. Mind Cure Health Recent Developments

Table 139. Entheon Biomedical Basic Information List

Table 140. Entheon Biomedical Description and Business Overview

Table 141. Entheon Biomedical Psychedelic Drugs Products, Services and Solutions

Table 142. Revenue (US$ Million) in Psychedelic Drugs Business of Entheon Biomedical (2018-2023)

Table 143. Entheon Biomedical Recent Developments

Table 144. North America Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)

Table 145. North America Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)

Table 146. Europe Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)

Table 147. Europe Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)

Table 148. Asia-Pacific Psychedelic Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 149. Asia-Pacific Psychedelic Drugs Market Size by Region (2018-2023) & (US$ Million)

Table 150. Asia-Pacific Psychedelic Drugs Market Size by Region (2024-2029) & (US$ Million)

Table 151. Asia-Pacific Psychedelic Drugs Market Share by Region (2018-2023)

Table 152. Asia-Pacific Psychedelic Drugs Market Share by Region (2024-2029)

Table 153. Latin America Psychedelic Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 154. Latin America Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)

Table 155. Latin America Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)

Table 156. Middle East & Africa Psychedelic Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029

Table 157. Middle East & Africa Psychedelic Drugs Market Size by Country (2018-2023) & (US$ Million)

Table 158. Middle East & Africa Psychedelic Drugs Market Size by Country (2024-2029) & (US$ Million)

Table 159. Psychedelic Drugs Market Trends

Table 160. Psychedelic Drugs Market Drivers

Table 161. Psychedelic Drugs Market Challenges

Table 162. Psychedelic Drugs Market Restraints

Table 163. Research Programs/Design for This Report

Table 164. Key Data Information from Secondary Sources

Table 165. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Psychedelic Drugs Market Size Year-over-Year 2018-2029 & (US$ Million)

Figure 2. Global Psychedelic Drugs Market Size (US$ Million), 2018 VS 2022 VS 2029

Figure 3. Global Psychedelic Drugs Market Share by Regions: 2022 VS 2029

Figure 4. Global Psychedelic Drugs Forecasted Market Size Share by Region (2024-2029)

Figure 5. North America Psychedelic Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 6. Europe Psychedelic Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 7. Asia-Pacific Psychedelic Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 8. Latin America Psychedelic Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 9. Middle East & Africa Psychedelic Drugs Market Size Growth Rate (2018-2029) & (US$ Million)

Figure 10. Product Picture of Psilocybin

Figure 11. Global Psilocybin Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 12. Product Picture of LSD

Figure 13. Global LSD Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 14. Product Picture of MDMA

Figure 15. Global MDMA Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 16. Product Picture of DMT

Figure 17. Global DMT Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 18. Product Picture of Ketamine

Figure 19. Global Ketamine Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 20. Product Picture of Others

Figure 21. Global Others Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 22. Global Psychedelic Drugs Market Size Share by Type: 2022 & 2029

Figure 23. North America Psychedelic Drugs Revenue Market Share by Type (2018-2029)

Figure 24. Europe Psychedelic Drugs Revenue Market Share by Type (2018-2029)

Figure 25. Asia-Pacific Psychedelic Drugs Revenue Market Share by Type (2018-2029)

Figure 26. Latin America Psychedelic Drugs Revenue Market Share by Type (2018-2029)

Figure 27. Middle East and Africa Psychedelic Drugs Revenue Market Share by Type (2018-2029)

Figure 28. Depressive Disorders Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 29. Post-Traumatic Stress Disorders Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 30. Substance Abuse Disorders Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 31. Obsessive Compulsive Disorders Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 32. Others Market Size (US$ Million) & YoY Growth (2018-2029)

Figure 33. Global Psychedelic Drugs Market Size Share by Application: 2022 & 2029

Figure 34. North America Psychedelic Drugs Revenue Market Share by Application (2018-2029)

Figure 35. Europe Psychedelic Drugs Revenue Market Share by Application (2018-2029)

Figure 36. Asia-Pacific Psychedelic Drugs Revenue Market Share by Application (2018-2029)

Figure 37. Latin America Psychedelic Drugs Revenue Market Share by Application (2018-2029)

Figure 38. Middle East and Africa Psychedelic Drugs Revenue Market Share by Application (2018-2029)

Figure 39. Psychedelic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

Figure 40. Global Top 5 and Top 10 Players Psychedelic Drugs Market Share in 2022

Figure 41. North America Psychedelic Drugs Market Share by Country (2018-2029)

Figure 42. United States Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 43. Canada Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 44. Germany Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 45. France Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 46. U.K. Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 47. Italy Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 48. Russia Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 49. Nordic Countries Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 50. Asia-Pacific Psychedelic Drugs Market Share by Region (2018-2029)

Figure 51. China Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 52. Japan Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 53. South Korea Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 54. Southeast Asia Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 55. India Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 56. Australia Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 57. Latin America Psychedelic Drugs Market Share by Country (2018-2029)

Figure 58. Mexico Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 59. Brazil Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 60. Middle East & Africa Psychedelic Drugs Market Share by Country (2018-2029)

Figure 61. Turkey Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 62. Saudi Arabia Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 63. UAE Psychedelic Drugs Market Size (2018-2029) & (US$ Million)

Figure 64. Bottom-up and Top-down Approaches for This Report

SELECT A FORMAT

Added to Cart

Single User

Electronic

$3350

Single User License

Multi User

Electronic

$5025

Multi User License

Enterprise License

Electronic

$6700

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Psychedelic Drugs - Global Market Insights and Sales Trends 2024

Published Date: 2023-12-27

Report Code: QYRE-Auto-38Y9909

Psychedelic Drugs - Global Market Insights and Sales Trends 2024

FEATURED COMPANIES

Psychedelic Drugs - Market Size

Psychedelic Drugs - Market

Report Objectives

Key Features of The Study:

Scope of Psychedelic Drugs - Market Report

Core Chapters

FAQ for this report

What are the Application segmentation covered in the Psychedelic Drugs - Market report?

What are the Type segmentation covered in the Psychedelic Drugs - Market report?

FEATURED COMPANIES